Hoosier's sticky shows: AMBS has over 138 paten

Hoosier's sticky shows:

AMBS has over 138 patents, licenses, options to license/patent assays in its product pipeline, and they hold rights to other intellectual property as well.

MANF: AMBS has obtained worldwide rights to MANF covering all neurological indications. They include but are not limited to:

1). Parkinson's Disease (PD)
2). Amyotrophic Lateral Sclerosis (ALS) - Lou Gehrig's Disease -
3). Ischemic Heart Disease
4). Alzheimer's Disease (AD)
5). Huntington's Disease
6). Traumatic Brain Injury/ Chronic Traumatic Encephalopathy (TBI/CTE)

https://investorshangout.com/post/view?id=2824848

The Edison article shows Herantis owns US rights to MANF. I think GC clarified that in a tweet a while back. Anyone recall?

Quote:

---

Neuroprotective factor CDNF in PD

CDNF, a naturally occurring protein in the human body, was discovered at the University of Helsinki, through work by professor Mart Saarma (on the scientific board at Herantis). Herantis is developing its innovative recombinant factor CDNF for the treatment of a range of neurodegenerative conditions. This protein-based therapy is being evaluated for its potential neuroprotective and neuro restorative properties in PD. Herantis believes this is the only scalable, recombinant factor CDNF in development globally. Herantis has patented the global rights to CDNF and the US rights to the closely related protein mesencephalic astrocyte-derived neurotrophic factor (MANF) (US-based Amarantus Biosciences has a MANF treatment in pre-clinical development) for the treatment of neurological conditions including PD, epilepsy and ischaemic brain injury.

CDNF and MANF are a novel family of neurotrophic factors that are located and secreted by the endoplasmic reticulum (ER) (an intracellular organelle that functions as a protein manufacturing and packaging system). CDNF’s exact mode of action in PD is still being evaluated as it appears to exert its neuroprotective function through multiple mechanisms of action. In addition to PD, CDNF could have utility in amyotrophic lateral sclerosis and Huntington’s disease (both are severe and incurable neurodegenerative disease) as preclinical data support further development in this area. This report, however, focuses on the PD opportunity given its Phase I/II clinical trial status.

In preclinical studies CDNF has protected dopaminergic (DA) neurons, restored function to degraded neurons and thus affected motor and non-motor symptoms of PD in addition to slowing down disease progression. If replicated in human clinical trials these attributes would enable CDNF to be a truly differentiated treatment for PD and could address two major unmet clinical needs in PD patients (treatment of non-motor symptoms and slowdown of disease progression) in addition to efficacious treatment of the well-known motor symptoms (eg tremor, dyskinesia, rigidity, loss of autonomic movement, speech changes).

---

https://www.edisoninvestmentresearch.com/rese...harma/full